Mobocertinib
Sign in to save this workspacePrimary targets: EGFR · FDA status: FDA Approval Withdrawn
Selectivity scorecard
KISS
97.22
Gini
0.757
CATDS
0.035
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Mobocertinib. Strongest target: EGFR at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | EGFR | 100.0% | 0.0% |
| 2 | ERBB2_HER2 | 99.8% | 0.2% |
| 3 | BLK | 99.7% | 0.3% |
| 4 | ERBB4_HER4 | 99.6% | 0.4% |
| 5 | BMX_ETK | 98.1% | 1.9% |
| 6 | BTK | 97.4% | 2.6% |
| 7 | ACK1 | 97.4% | 2.6% |
| 8 | JAK3 | 97.2% | 2.8% |
| 9 | TXK | 97.1% | 2.9% |
| 10 | ITK | 94.4% | 5.6% |
| 11 | TEC | 91.6% | 8.4% |
| 12 | FRK_PTK5 | 83.3% | 16.7% |
| 13 | BRK | 61.5% | 38.5% |
| 14 | LYN | 46.6% | 53.4% |
| 15 | RET | 37.2% | 62.8% |
| 16 | LRRK2 | 35.1% | 64.9% |
| 17 | ABL1 | 33.0% | 67.0% |
| 18 | HIPK4 | 31.6% | 68.4% |
| 19 | YES_YES1 | 28.7% | 71.3% |
| 20 | SRMS | 28.3% | 71.7% |
Selectivity landscape
Where Mobocertinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Mobocertinib.
Annotations
Sign in to read and post annotations.
Loading…